buyWeak
Preston Klassen bought $96k of RGLS
President & Head of R & D at Regulus Therapeutics Inc.. 12,000 shares at an average of $7.99, traded Jun 3, 2025, filed Jun 4, 2025.
Conviction score
36Value
$96k
12,000 shares
Holdings after
48,055
+33% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +10Trade size$96k at market
- +6Relative to holdingsHoldings up 33%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-081715, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2025 | POpen-market purchase Common Stock | +12,000 | $7.99 | $96k | 48,055 | Jun 4, 2025 |
Related signals
Other insiders at Regulus Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Regulus Therapeutics Inc. | David Baltimore director | $21k 19,610 shares | +766% | |
| 46Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $54k 50,000 shares | +24% | |
| 27Weak | Regulus Therapeutics Inc. | Christopher Ray Aker Sr. VP & General Counsel | $55k 43,635 shares | -47% | |
| 34Weak | Regulus Therapeutics Inc. | Crispina Calsada Chief Financial Officer | $55k 43,804 shares | -49% | |
| 41Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $160k 127,054 shares | -38% | |
| 31Weak | Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $40k 31,445 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.